Syncona, a FTSE250 company focused on founding, building and funding healthcare companies, and Mass General Brigham Ventures, an early-stage venture capital firm, led a $56m Series B round in SwanBio Therapeutics, a gene therapy company. "Since our initial investment, SwanBio has made excellent progress, including rapidly advancing its lead program for AMN toward the clinic. In parallel, the company has built the platform capabilities that will allow it to advance its broader pipeline of AAV gene therapies for spinal cord-related disorders toward clinical development," Chris Hollowood, Syncona CIO.